GenViro!
The design above is in many regards similar to the direct antibody antigen approaches favored by some of the competitive companies in the Covid-19 testing field. But the major difference (magic) is that the approach used by the company in its GenViro! product allows for swift (15 seconds or less) results using a minimum of blood from a finger prick. As of this writing, work has commenced on the product specification above with components such as the platinum electrodes, platinum carbon paste, industrial films (several types) to make the biosensor, and perhaps a new impedance chip for the meter. The company is operating on an 8-week development schedule and is some 10 days into this schedule. The current development cycle is considered advanced development. For FDA EUA filing and the granting of a Pre-EUA by the FDA, the company is preparing its final working concept filing, to be completed within days of this writing.
On April 1, 2020 the company plans to begin development work on its second product design, a confirmation test for Covid-19. This test, a hybrid but direct antibody/antigen (IGG) method, again making use of the company’s expertise in biosensors, will be designed to be used on those the tested Positive Covid-19, and those that tested Negative but are suspected to be false Negatives. This product design is not yet in the advanced development cycle.
The DECN Theme Song, "Tomorrow, Tomorrow …."
